GlassScriptPhysician profile
Daniela Elena Matei
NPI 1558327486
$63,999.84
in general payments reported to CMS, 2019-2025
16 companies · $419 in 2025
The $419 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,910 · 2020: $18K · 2021: $15K · 2022: $12K · 2023: $5,401 · 2024: $3,255 · 2025: $419.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,550 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $250 · Travel and Lodging: $146 · Food and Beverage: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,550.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $249.97 |
| Travel and Lodging | $146.48 |
| Food and Beverage | $127.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $28,834.56 | 2020-2024 | Zejula |
| Astrazeneca Pharmaceuticals LP | $23,272.27 | 2019-2025 | |
| Radius Health, INC. | $3,560.01 | 2019 | |
| Eli Lilly and Company | $2,625.00 | 2021 | |
| Merck Sharp & Dohme LLC | $1,533.28 | 2020-2025 | Lynparza, Keytruda |
| Clovis Oncology, INC. | $1,500.00 | 2020 | |
| Seagen INC. | $1,375.00 | 2021 | |
| Emd Serono Research & Development Institute, INC. | $950.00 | 2023 | |
| Taiho Oncology, INC. | $223.93 | 2025 | |
| Foundation Medicine, INC. | $50.52 | 2023 | |
| Pfizer INC. | $32.74 | 2024 | |
| Abbvie INC. | $22.28 | 2024 | |
| Tanabe Pharma America, INC. | $20.25 | 2025 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Matei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.